Company Overview of AstraZeneca AB
AstraZeneca AB researches, develops, manufactures, and markets pharmaceuticals for gastrointestinal, cardiovascular, respiratory, and pain control. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.
Sodertalje, 151 85
Founded in 1913
Key Executives for AstraZeneca AB
Compensation as of Fiscal Year 2016.
AstraZeneca AB Key Developments
Aspen Global Incorporated Announces Signing of a Commercialization Agreement with AstraZeneca AB and AstraZeneca UK
Jun 9 16
Aspen Global Incorporated (AGI), has signed an agreement with AstraZeneca AB and AstraZeneca UK (AstraZeneca) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca's global (excluding the USA) anaesthetics portfolio. AstraZeneca's anaesthetics portfolio comprises seven established medicines, namely Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest) ("the Portfolio"). The products in the Portfolio are sold in more than one hundred countries worldwide including China, Japan, Australia and Brazil. These products generated revenue of USD 592 million in the year ended 31 December 2015. In terms of the concluded agreement, as consideration for the commercialisation rights, AGI will pay USD 520 million and double-digit percentage royalties on sales of the Portfolio. Additionally AGI will make sales related payments of up to USD 250 million based on sales in the 24 months following completion. AGI and AstraZeneca have also signed a supply agreement whereby AstraZeneca will supply the anaesthetic products to AGI.
China Medical System Holdings Ltd. Enters License Agreement with AstraZeneca AB in Respect of Plendil
Apr 25 16
China Medical System Holdings Ltd. entered into the Exclusive License Agreement with AstraZeneca AB, pursuant to which AstraZeneca AB grants an exclusive license to the Company for the Commercialisation of the Licensed Products in the PRC, and in consideration of which, the Company has agreed to pay a total license fee of USD 310 million to AstraZeneca AB.
Cerulean Pharma Inc. Announces Clinical Collaboration with AstraZeneca AB and National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
Nov 17 15
Cerulean Pharma Inc. announced that it has entered into a collaboration with AstraZeneca AB (AstraZeneca) and the National Cancer Institute (NCI), to study LYNPARZA™ (olaparib) and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca’s LYNPARZA, a poly ADP ribose polymerase (PARP) inhibitor, and CRLX101, Cerulean’s inhibitor of topoisomerase 1 (Top1). The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch. The discovery of new, therapeutic combinations that improve patient outcomes is a core part of strategy. The combination of LYNPARZA with CRLX101 provides an opportunity to investigate the potential of LYNPARZA beyond patients with mutations in homologous repair genes such as BRCA. The scientific rationale for combining PARP inhibitors with Top1 inhibitors is well understood. Simply stated, Top1 inhibitors damage DNA, and PARP inhibitors prevent DNA damage repair. CRLX101 is a Top1 inhibitor. Top1 inhibitors trap DNA-topoisomerase complexes, preventing ligation and resulting in persistent single-stranded breaks. LYNPARZA is a PARP inhibitor that exploits tumor DNA damage repair pathway deficiencies to preferentially kill cancer cells. PARP’s main role is to detect and signal single-strand DNA breaks to the enzymatic complex that repairs single-strand DNA breaks. Under this collaboration, AstraZeneca will supply LYNPARZA, Cerulean will supply CRLX101, and the NCI will fund and conduct the clinical trial under Cooperative Research and Development Agreements with the companies. The clinical trial of LYNPARZA in combination with CRLX101 in small cell lung cancer will enroll approximately 55 patients with enrollment expected to commence in the first half of 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|